Palantir Bioceuticals, formerly IFAN Financial, Inc., (OTC: IFAN) is proud to announce its unique approach to treating mental illness. Palantir Bioceuticals is a biopharmaceutical company providing holistic solutions for mental illness. Palantir Bioceuticals uses a radical innovation called Psychedelics-Assisted Psychotherapy (PAP), a supervised use of ketamine, MDMA, psilocybin, LSD, and ibogaine as part of sophisticated psychotherapy programs to treat depression, anxiety, and PTSD.
Ketamine is legal, safe, and fast-acting when administered under medical supervision. Psychedelic exploration can bring about significant changes after the first session. This unique therapy program combines psychedelics with therapeutic techniques to help patients discover the root causes of their pain. Our therapists help patients to integrate the insights from their psychedelic experience into daily life and, ideally, to prevent a relapse.
Traditional treatments for mental illness include antidepressants, antipsychotics, sleeping pills, mild tranquilizers, lithium, and other mood stabilizers. However, these drugs have a variety of side effects.
Research from the Johns Hopkins Center for Psychedelic and Consciousness Research is at the forefront of exploring innovative treatments using psilocybin. Scientists and medical experts now fully appreciate psilocybin’s effects on the brain and mind and its potential as a therapeutic drug. Allied Market Research estimates that the global mental health market will grow 3.5% from 2021 to 2030 and reach $537 billion in 2030.
Palantir Bioceuticals offers holistic alternatives to meet the growing demand for mental health solutions. Palantir Bioceuticals is committed to transforming mental health by acquiring medical properties and leasing them to management companies dedicated to natural health and psychedelic psychotherapy.
Name of the company: Palantir Bioceuticals, INC, formally IFAN Financial, INC.
Interlocutor: Markus Anderson
E-mail: Send e-mail
Country: United States